Jenburkt Pharmaceuticals Limited (JENBURPH) Fair Value & Analysis
Healthcare · IN · Market cap ₹4.9B
Fair value as of: Jul 5, 2026
From 26 valuation models · updated 3 days ago
Share price −1.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹955.45 – ₹1,368 · fair‑value band ₹594.42 – ₹1,673 · the ₹1,116 price screens above the ₹1,038 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jenburkt Pharmaceuticals Limited (JENBURPH) currently trades at ₹1,116, while our model-based Fair Value estimate is ₹1,038 — implying the stock looks roughly 7.0% overvalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Jenburkt Pharmaceuticals Limited generated revenue of ₹1.7B at a net margin of 20.6%. Revenue grew 8.7% year over year. It earns a return on equity of 18.8%. Net debt stands at ₹7.8M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹594.42 (bear case) to ₹1,673 (bull case); at ₹1,116, the current price sits within that range. The share trades about 20% below its 52-week high and 18% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside — at -7%, JENBURPH screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. It offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. The company offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names. The company provides its products through stockists, doctors, pharmacies, chemists, large government, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Jenburkt Pharmaceuticals Limited reported revenue of ₹1.7B in FY2026 versus ₹1.2B in FY2022, a compound +8.1%/yr. Reported net income was ₹347M in FY2026, compounding +11.7%/yr from FY2022.
Is JENBURPH fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jenburkt Pharmaceuticals Limited (JENBURPH) undervalued?
What is the fair value of JENBURPH?
What is the quality score of JENBURPH?
What is the revenue of Jenburkt Pharmaceuticals Limited (JENBURPH)?
What is the net profit margin of JENBURPH?
Does Jenburkt Pharmaceuticals Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.